Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
(2014) In Leukemia 28(8). p.1573-1585- Abstract
- In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, while dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who... (More)
- In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, while dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism are provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed.Leukemia accepted article preview online, 5 February 2014; doi:10.1038/leu.2014.60. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4335623
- author
- Dimopoulos, M A
; Leleu, X
; Palumbo, A
; Moreau, P
; Delforge, M
; Cavo, M
; Ludwig, H
; Morgan, G J
; Davies, F E
; Sonneveld, P
; Schey, S A
; Zweegman, S
; Hansson, Markus
LU
; Weisel, K
; Mateos, M V
; Facon, T
and San Miguel, J F
(Less) - organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Leukemia
- volume
- 28
- issue
- 8
- pages
- 1573 - 1585
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:24496300
- wos:000341334600001
- scopus:84905695380
- pmid:24496300
- ISSN
- 1476-5551
- DOI
- 10.1038/leu.2014.60
- language
- English
- LU publication?
- yes
- id
- 13e2ab16-f6f3-4198-8d71-4634545433c0 (old id 4335623)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24496300?dopt=Abstract
- date added to LUP
- 2016-04-01 10:49:02
- date last changed
- 2022-03-27 19:47:22
@article{13e2ab16-f6f3-4198-8d71-4634545433c0,
abstract = {{In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, while dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism are provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed.Leukemia accepted article preview online, 5 February 2014; doi:10.1038/leu.2014.60.}},
author = {{Dimopoulos, M A and Leleu, X and Palumbo, A and Moreau, P and Delforge, M and Cavo, M and Ludwig, H and Morgan, G J and Davies, F E and Sonneveld, P and Schey, S A and Zweegman, S and Hansson, Markus and Weisel, K and Mateos, M V and Facon, T and San Miguel, J F}},
issn = {{1476-5551}},
language = {{eng}},
number = {{8}},
pages = {{1573--1585}},
publisher = {{Nature Publishing Group}},
series = {{Leukemia}},
title = {{Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.}},
url = {{http://dx.doi.org/10.1038/leu.2014.60}},
doi = {{10.1038/leu.2014.60}},
volume = {{28}},
year = {{2014}},
}